🟢 GeneDx is trading 4.1% up today after reporting a return to adjusted profitability and strong Q2 revenue

GeneDx is trading 4.1% up now at $70.61 after reporting better-than-expected second quarter 2026 revenue and a return to adjusted profitability.

• The company reaffirmed its full-year guidance and highlighted 32% growth in exome and genome volume.
• Management signaled stabilization following a guidance cut in May, while broader biotech and equity market rallies provided additional tailwinds.